Vertex Handed Subpoena Over Good Laboratory Practices

Cystic fibrosis drugmaker Vertex Pharmaceuticals received a subpoena from the Department of Justice requesting documents related to good laboratory practices in a bioanalytical laboratory, according to an SEC filing detailing quarterly financial results.

Good laboratory practices govern the conduct of nonclinical safety studies, which work to ensure the quality, integrity and reliability of the study data.

Vertex spokesman Zach Barber said the company does not view the subpoena as material to business, and that it does not have any impact on the safety, efficacy and development of its medicines.